Menu
Search
|

Menu

Close
X

Jounce Therapeutics Inc JNCE.OQ (NASDAQ Stock Exchange Global Select Market)

3.52 USD
-0.05 (-1.40%)
As of Sep 13
Previous Close 3.57
Open 3.59
Volume 28,468
3m Avg Volume 41,263
Today’s High 3.61
Today’s Low 3.51
52 Week High 7.32
52 Week Low 2.67
Shares Outstanding (mil) 32.97
Market Capitalization (mil) 157.61
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY19
11
FY18
65
FY17
72
FY16
37
EPS (USD)
FY19
-0.376
FY18
-0.842
FY17
-0.540
FY16
-6.969
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
2.43
7.90
Price to Book (MRQ)
vs sector
1.67
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.64
LT Debt to Equity (MRQ)
vs sector
0.00
12.61
Return on Investment (TTM)
vs sector
-15.60
12.69
Return on Equity (TTM)
vs sector
-26.11
17.13

EXECUTIVE LEADERSHIP

Perry Karsen
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Richard Murray
President, Chief Executive Officer, Director, Since 2014
Salary: $525,000.00
Bonus: $236,300.00
Kimberlee Drapkin
Chief Financial Officer, Treasurer, Since 2015
Salary: $370,000.00
Bonus: $116,600.00
Hugh Cole
Chief Business Officer, Head of Corporate Development, Since 2017
Salary: $147,337.00
Bonus: $103,400.00
Elizabeth Trehu
Chief Medical Officer, Since 2015
Salary: $398,500.00
Bonus: $125,600.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

780 Memorial Dr
CAMBRIDGE   MA   02139-4613

Phone: +1857.2593840

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.

SPONSORED STORIES